Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress
May 06, 2021 16:01 ET
|
Codiak BioSciences, Inc.
– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year – – Data from multiple preclinical programs to be presented...
Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
April 27, 2021 16:30 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Data from Codiak’s exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology
April 22, 2021 07:00 ET
|
Codiak BioSciences, Inc.
– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo – – Novel engineered exosome therapeutic candidate...
Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways
April 10, 2021 08:30 ET
|
Codiak BioSciences, Inc.
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021 – ...
Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
March 17, 2021 07:30 ET
|
Codiak BioSciences, Inc.
– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients – – On track to report biomarker, safety and...
Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting
March 10, 2021 16:38 ET
|
Codiak BioSciences, Inc.
– Healthy volunteer clinical data for exoIL-12 accepted as a late-breaking abstract – – Preclinical data demonstrating single-agent complete responses following exosome delivery of antisense...
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option
February 17, 2021 16:30 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of...
Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock
February 11, 2021 22:18 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of...
Codiak Announces Proposed Public Offering of Common Stock
February 09, 2021 16:17 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics...
Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients
February 04, 2021 07:30 ET
|
Codiak BioSciences, Inc.
– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity without systemic IL-12 exposure – – Plan to initiate multi-dose study in CTCL patients, with data anticipated by year-end...